Discuss with your doctor or care team
Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.
Trial purpose
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.
 |
NATIONAL TRIAL REFERENCE NUMBER | NCT05007106 |
 |
Conditions | Cholangiocarcinoma, Endometrial Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Hepatocellular Carcinoma, Ovarian Neoplasms, Squamous Cell Carcinoma Of Head And Neck, Stomach Neoplasms, Triple Negative Breast Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms |
 |
Age Range | 18+ |
 |
Sex | All |
|
Current trial phase | 1 |
|
Trial start and end dates | [09-16-2021] [08-12-2026] |
About the trial
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Cholangiocarcinoma, Endometrial Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Hepatocellular Carcinoma, Ovarian Neoplasms, Squamous Cell Carcinoma Of Head And Neck, Stomach Neoplasms, Triple Negative Breast Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms
Phase 2
In Phase 2 trials, researchers try to find out if a treatment works in about 100 to 500 participants – usually people who have the health condition the treatment is intended to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial locations (0)
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.